Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gilteritinib”

54 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 54 results

Early research (Phase 1)Study completedNCT02181660
What this trial is testing

Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia (AML)
Astellas Pharma Inc 24
Testing effectiveness (Phase 2)Study completedNCT02927262
What this trial is testing

ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

Who this might be right for
Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation
Astellas Pharma Global Development, Inc. 98
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06667973
What this trial is testing

Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaFLT3 Gene MutationAdult AML+1 more
Gruppo Italiano Malattie EMatologiche dell'Adulto 80
Large-scale testing (Phase 3)Not Yet RecruitingNCT07407140
What this trial is testing

VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML

Who this might be right for
AML, Adult
Institute of Hematology & Blood Diseases Hospital, China 300
Testing effectiveness (Phase 2)Looking for participantsNCT06561880
What this trial is testing

The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation

Who this might be right for
FLT3 Gene MutationAML
Institute of Hematology & Blood Diseases Hospital, China 36
Large-scale testing (Phase 3)Active Not RecruitingNCT04027309
What this trial is testing

Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndrome With Excess Blasts-2
Stichting Hemato-Oncologie voor Volwassenen Nederland 777
Testing effectiveness (Phase 2)Looking for participantsNCT06696183
What this trial is testing

Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment

Who this might be right for
AML - Acute Myeloid Leukemia
Technische Universität Dresden 60
Large-scale testing (Phase 3)Looking for participantsNCT04293562
What this trial is testing

Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Who this might be right for
Acute Myeloid Leukemia
Children's Oncology Group 1,186
Testing effectiveness (Phase 2)Looking for participantsNCT06235801
What this trial is testing

A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

Who this might be right for
Myeloid Leukemia
M.D. Anderson Cancer Center 20
Early research (Phase 1)Study completedNCT04699877
What this trial is testing

Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal Function

Who this might be right for
Renal ImpairedGilteritinibNormal Renal Function+1 more
Astellas Pharma Global Development, Inc. 17
Testing effectiveness (Phase 2)Ended earlyNCT02495233
What this trial is testing

ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Who this might be right for
Non-Small-Cell Lung Cancer
Astellas Pharma Global Development, Inc. 10
Testing effectiveness (Phase 2)WithdrawnNCT05279859
What this trial is testing

Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies

Who this might be right for
Acute Myeloid Leukemia
Erasca, Inc.
Large-scale testing (Phase 3)Not Yet RecruitingNCT07425808
What this trial is testing

FLT3-ITD Targeted Therapy in Fit AML Patients

Who this might be right for
AML (Acute Myeloid Leukemia)
European Organisation for Research and Treatment of Cancer - EORTC 230
Testing effectiveness (Phase 2)Study completedNCT02310321
What this trial is testing

ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.

Who this might be right for
Acute Myeloid LeukemiaFLT3-mutated Acute Myeloid Leukemia
Astellas Pharma Inc 97
Testing effectiveness (Phase 2)Looking for participantsNCT07259707
What this trial is testing

Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML

Who this might be right for
Acute Myeloid LeukemiaFLT3 Internal Tandem Duplication PositiveIntermediate Risk Acute Myeloid Leukemia+1 more
First Affiliated Hospital of Zhejiang University 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT05199051
What this trial is testing

Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML

Who this might be right for
AMLLeukaemia (Acute Myeloid)
Centre Antoine Lacassagne 19
Not applicableStudy completedNCT06734585
What this trial is testing

Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant

Who this might be right for
Acute Myeloid Leukemia
Astellas Pharma Singapore Pte. Ltd. 114
Testing effectiveness (Phase 2)Active Not RecruitingNCT05520567
What this trial is testing

Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia (AML)FLT3-mutated Acute Myeloid Leukemia
Astellas Pharma Global Development, Inc. 70
Early research (Phase 1)Looking for participantsNCT06225427
What this trial is testing

Gilteritinib for the Treatment of ALK NSCLC

Who this might be right for
Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8
University of Michigan Rogel Cancer Center 30
Early research (Phase 1)Study completedNCT02456883
What this trial is testing

Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsPharmacokinetics of 14C-labeled Gilteritinib
Astellas Pharma Global Development, Inc. 6
Load More Results